December 15, 2016 / 9:17 PM / in a year

BRIEF-Agios provides update on PKR Program

Dec 15 (Reuters) - Agios Pharmaceuticals Inc

* Agios Pharmaceuticals Inc- Withdrew its investigational new drug application following a verbal notification of a clinical hold from U.S. FDA

* Agios Pharmaceuticals Inc- Decisions do not affect company’s ongoing global phase 2 study (DRIVE PK) for AG-348

* Agios Pharmaceuticals Inc- It is no longer developing its second pyruvate kinase-R (PKR) activator, AG-519

* Agios provides update on PKR Program Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below